KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
On March23, 2017, KalVista Pharmaceuticals, Inc. (the Company)
held a special meeting of its stockholders at which the Companys
stockholders voted on the proposals set forth below. The final
results regarding each proposal are set forth below.
Proposal No.1: Approval of the 2017 Equity Incentive Plan:
|
Votes Cast For |
Votes Cast Against |
Number of Abstentions |
Number of BrokerNon-Votes |
|||
|
7,232,865 |
110,262 |
Proposal No.2: Approval of the 2017 Employee Stock Purchase Plan:
|
Votes Cast For |
Votes Cast Against |
Number of Abstentions |
Number of BrokerNon-Votes |
|||
|
7,303,409 |
40,245 |
2
About KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV)
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001. KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Recent Trading Information
KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) closed its last trading session up +0.09 at 7.78 with 11,819 shares trading hands.
